RU2012148214A - Композиции и способы для лечения нарушений зрения - Google Patents

Композиции и способы для лечения нарушений зрения Download PDF

Info

Publication number
RU2012148214A
RU2012148214A RU2012148214/15A RU2012148214A RU2012148214A RU 2012148214 A RU2012148214 A RU 2012148214A RU 2012148214/15 A RU2012148214/15 A RU 2012148214/15A RU 2012148214 A RU2012148214 A RU 2012148214A RU 2012148214 A RU2012148214 A RU 2012148214A
Authority
RU
Russia
Prior art keywords
alkyl
substituted
group
retinal
oil
Prior art date
Application number
RU2012148214/15A
Other languages
English (en)
Russian (ru)
Inventor
Урсула В. СТАУБЛИ
Юн-Синь ЛИ
Алан С. ФОСТЕР
Original Assignee
Аллерган, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аллерган, Инк. filed Critical Аллерган, Инк.
Publication of RU2012148214A publication Critical patent/RU2012148214A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2012148214/15A 2010-04-15 2011-04-13 Композиции и способы для лечения нарушений зрения RU2012148214A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32463210P 2010-04-15 2010-04-15
US61/324,632 2010-04-15
PCT/US2011/032325 WO2011130411A1 (en) 2010-04-15 2011-04-13 Compositions and methods for treating visual disorders

Publications (1)

Publication Number Publication Date
RU2012148214A true RU2012148214A (ru) 2014-05-20

Family

ID=44009992

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012148214/15A RU2012148214A (ru) 2010-04-15 2011-04-13 Композиции и способы для лечения нарушений зрения

Country Status (8)

Country Link
US (1) US20110257186A1 (cg-RX-API-DMAC7.html)
EP (1) EP2558100A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013523892A (cg-RX-API-DMAC7.html)
KR (1) KR20130092976A (cg-RX-API-DMAC7.html)
AU (1) AU2011239683A1 (cg-RX-API-DMAC7.html)
CA (1) CA2796345A1 (cg-RX-API-DMAC7.html)
RU (1) RU2012148214A (cg-RX-API-DMAC7.html)
WO (1) WO2011130411A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201600127037A1 (it) * 2016-12-15 2018-06-15 Oftalab S R L Soluzione oftalmica di verde di lissamina e suo uso in oftalmologia
CN109908327A (zh) * 2019-03-12 2019-06-21 广州陈锦济生物科技有限公司 一种用于治疗近视的眼药水及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
PL378366A1 (pl) * 2003-01-13 2006-04-03 Cortex Pharmaceuticals, Inc. Sposób leczenia osłabienia funkcji poznawczych spowodowanego deprywacją snu i stresem
EP2010174A4 (en) * 2006-04-20 2012-05-09 Univ California PHARMACOLOGICAL MODULATION OF POSITIVE AMPA-RECEPTOR MODULATOR EFFECT ON NEUROTROPHINEXPRESSION
US20080139472A1 (en) * 2006-10-06 2008-06-12 The Regents Of The University Of California Upregulating bdnf levels to mitigate mental retardation
ZA200904826B (en) * 2007-01-03 2010-09-29 Cortex Pharma Inc 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
CA2674321A1 (en) 2007-01-03 2008-07-17 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
NZ584098A (en) * 2007-09-20 2012-05-25 Cortex Pharma Inc 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses

Also Published As

Publication number Publication date
JP2013523892A (ja) 2013-06-17
EP2558100A1 (en) 2013-02-20
AU2011239683A1 (en) 2012-11-08
WO2011130411A1 (en) 2011-10-20
KR20130092976A (ko) 2013-08-21
CA2796345A1 (en) 2011-10-20
US20110257186A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
RU2005118107A (ru) Ингибиторы гистондеацетилазы для лечения офтальмологических неоваскулярных или отечных нарушений и заболеваний
CA3045733C (en) Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
JP2009511632A5 (cg-RX-API-DMAC7.html)
ES2399314T3 (es) Gamma lactamas sustituidas como agentes terapeúticos
HRP20220138T1 (hr) Peptidni pripravci i postupci uporabe
US7105512B2 (en) Ophthalmic aqueous pharmaceutical preparation
JP2018529693A5 (cg-RX-API-DMAC7.html)
RU2020118178A (ru) Лекарственные средства и композиции для доставки в глаз
CA2491313A1 (en) Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use
JP2018514590A5 (cg-RX-API-DMAC7.html)
RU2009145939A (ru) Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза
WO2020099925A3 (en) Peptides and pharmaceutical compositions for treating eye diseases
WO2017019808A1 (en) Compositions for the treatment of cataracts
WO2005055926A3 (en) Amelioration of cataracts, macular degeneration and other ophthalmic diseases
JP2010514733A5 (cg-RX-API-DMAC7.html)
JP2013523892A5 (cg-RX-API-DMAC7.html)
WO2020041344A4 (en) Methods and compositions for drugs to treat ophthalmic diseases
JP2018510855A5 (cg-RX-API-DMAC7.html)
US20170172959A1 (en) D-serine for the treatment of visual system disorders
KR20120081585A (ko) 안질환을 치료하기 위한 이소티오졸
JP2013513606A5 (cg-RX-API-DMAC7.html)
CA2796345A1 (en) Compositions and methods for treating visual disorders
RU2014106328A (ru) Фармацевтические композиции, содержащие 4-бром-n-(имидазолидин-2-илиден)-1н-бензимидазол-5-амин для лечения заболеваний сетчатки
JP6616403B2 (ja) 一酸化窒素供与カルノシン化合物
RU2016124102A (ru) Способ лечения офтальмологических расстройств с помощью соединений, обнаруженных в секретах железы мигательной перепонки

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20150827